Defective HIV Copies May Explain Most Persistent Viral Signals During Treatment
New Research Offers Reassurance for People Living With HIV Experiencing Detectable Viral Loads
By Robert Antonacci, M.D. and David Miller
For decades, achieving an “undetectable” viral load has been considered the gold standard of HIV treatment. Yet a small number of people living with HIV continue to show detectable levels of viral RNA in their blood despite strict adherence to antiretroviral therapy (ART), no evidence of drug resistance, and no signs of treatment failure.
New research from Johns Hopkins University may provide an important explanation—and considerable reassurance.
In a study published in Nature Communications, investigators found that the vast majority of these persistent viral signals are not caused by active, infectious HIV. Instead, they originate from defective copies of the virus that are incapable of causing new infections.
The phenomenon, known as non-suppressible viremia (NSV), has long puzzled clinicians and patients alike. Individuals with NSV maintain detectable HIV RNA levels even while taking effective ART and without evidence that the virus is actively replicating.
Researchers analyzed samples from more than 50 individuals receiving long-term HIV treatment. Their findings revealed that approximately 95% of the detectable viral RNA originated from highly defective viral genomes carrying abnormalities in a region known as the 5′ leader, a critical genetic segment involved in viral replication and packaging. These defects render the virus incapable of producing infectious particles.
The discovery has significant implications for both clinical care and patient peace of mind.
Many people living with HIV are taught that any detectable viral load could indicate treatment failure or increased risk of transmission. According to the study’s authors, that assumption may not apply in many NSV cases.
The defective viral copies identified in the study can still produce fragments of viral RNA that appear on laboratory tests, but they lack the ability to establish new infections. This means that detectable HIV RNA does not always equate to infectious virus.
For patients who experience persistent low-level viral detection despite excellent adherence, these findings may help reduce anxiety surrounding laboratory results and lessen concerns about viral rebound.
The researchers also developed a laboratory assay called CLAWS (Capturing 5′ Leader Anomalies Without Sequencing). The test can rapidly distinguish intact HIV RNA from defective HIV RNA without requiring extensive genetic sequencing.
The investigators believe this technology could help clinicians determine whether detectable viral RNA represents a true clinical concern or simply reflects harmless defective viral remnants. Such distinctions could become increasingly important in HIV cure research and in monitoring participants enrolled in experimental treatment interruption studies.
Implications for HIV Cure Research
The study also contributes to a growing understanding of HIV persistence
.
While ART effectively suppresses viral replication, HIV establishes long-lived reservoirs within infected immune cells. Most of these reservoirs contain defective proviruses that cannot generate infectious virus. The new findings suggest that these defective genomes may account for much of the residual viral material detected in blood during long-term therapy.
Researchers observed that defective viral RNA becomes increasingly dominant over time in individuals receiving long-term ART, further supporting the idea that residual detectable virus often reflects biological “noise” rather than active infection.
The findings do not change the importance of adherence to antiretroviral therapy, nor do they suggest that all detectable viral loads are benign. Genuine treatment failure, drug resistance, and viral rebound remain critical clinical concerns that require careful evaluation.
However, the study provides compelling evidence that many cases of persistent low-level viremia are driven by defective viral copies rather than infectious HIV. As diagnostic tools improve, clinicians may be better equipped to distinguish between harmless viral remnants and clinically significant viral activity.
For people living with HIV, that distinction could offer not only better medical guidance but also greater confidence in the effectiveness of modern treatment.
Global AIDS News Today will continue following developments in HIV reservoir research, cure strategies, and advances in viral load monitoring as they emerge.